Epcoritamab-bysp

{
  "id": "MLC-T-ONC-013382",
  "term": "Epcoritamab-bysp",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab-bysp contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab-bysp binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.",
  "synonyms": [
    "epcoritamab",
    "DuoBody-CD3xCD20",
    "anti-CD20/CD3 bispecific antibody GEN3013"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/epcoritamab-bysp/"
}